Search Result

Results for "

type 1 diabetes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (5) Akt (4) Amino Acid Decarboxylase (2) AMPK (1) Apoptosis (2) Arginase (1) Atg8/LC3 (1) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (2) Calcium Channel (1) Caspase (1) CCR (1) CD3 (3) CXCR (1) Drug Derivative (1) DYRK (2) Endogenous Metabolite (1) ERK (3) GCGR (1) GLUT (1) Hippo (MST) (2) Insulin Receptor (1) Interleukin Related (6) Isotope-Labeled Compounds (2) JNK (1) Lipoxygenase (1) LPL Receptor (2) MHC (1) mTOR (1) p38 MAPK (1) p62 (1) Phospholipase (1) PI3K (1) Potassium Channel (5) Reference Standards (2) STAT (1) Steroid Sulfatase (1) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Endocrinology (2) Infection (2) Inflammation/Immunology (19) Metabolic Disease (35) Neurological Disease (4)

By Targets:

11β-HSD (5)

Akt (4)

Amino Acid Decarboxylase (2)

AMPK (1)

Apoptosis (2)

Arginase (1)

Atg8/LC3 (1)

Autophagy (1)

Bacterial (1)

Biochemical Assay Reagents (2)

Calcium Channel (1)

Caspase (1)

CCR (1)

CD3 (3)

CXCR (1)

Drug Derivative (1)

DYRK (2)

Endogenous Metabolite (1)

ERK (3)

GCGR (1)

GLUT (1)

Hippo (MST) (2)

Insulin Receptor (1)

Interleukin Related (6)

Isotope-Labeled Compounds (2)

JNK (1)

Lipoxygenase (1)

LPL Receptor (2)

MHC (1)

mTOR (1)

p38 MAPK (1)

p62 (1)

Phospholipase (1)

PI3K (1)

Potassium Channel (5)

Reference Standards (2)

STAT (1)

Steroid Sulfatase (1)

TGF-beta/Smad (1)

TGF-β Receptor (1)

TNF Receptor (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (19)

Metabolic Disease (35)

Neurological Disease (4)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: C-type Lectin-like Receptors (CTLRs) Scavenger Receptor Class B type I (SR-BI） PCSK9

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10397

EP1013 F1013	Caspase	Metabolic Disease
EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes .

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-P99211

Otelixizumab ChAglyCD3; TRX 4	CD3	Metabolic Disease
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-B0254

Glipizide 2 Publications Verification CP 28720; K 4024	Potassium Channel	Metabolic Disease Cancer
Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-12462

WS3	Others	Inflammation/Immunology
WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes .

HY-B0254S

Glipizide-d11	Isotope-Labeled Compounds Potassium Channel	Metabolic Disease
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-120643A

BMS-823778	11β-HSD	Metabolic Disease
BMS-823778 was developed as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 to inhibit type 2 diabetes .

HY-P10612

Tetanus toxin peptide	Bacterial	Metabolic Disease
Tetanus toxin peptide is a specific peptide isolated from the toxin produced by Clostridium tetani. Tetanus toxin peptide can be used as an immunogen to induce diabetes in mice. Tetanus toxin peptide can be used in the study of type 1 diabetes .

HY-112290

MK-0736	11β-HSD	Cardiovascular Disease Metabolic Disease
MK-0736 is a *11β-HSD type 1* (11β-HSD1)** inhibitor that reduces blood pressure. MK-0736 can be used for type 2 diabetes and metabolic syndrome research .

HY-P991326

BL-9020 EDP-10; JHL-1311	Interleukin Related	Endocrinology
BL-9020 is a human monoclonal antibody (mAb) targeting NKp46/NCR1. BL-9020 can be used in type 1 diabetes mellitus research.

HY-B0254R

Glipizide (Standard) CP 28720 (Standard); K 4024 (Standard)	Reference Standards Potassium Channel	Metabolic Disease
Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-P991552

AFM15	CD3	Metabolic Disease Inflammation/Immunology
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .

HY-158525

A3G3S3 glycan A3G3S3 N-linked oligosaccharide	Biochemical Assay Reagents	Others
A3G3S3 glycan (A3G3S3 N-linked oligosaccharide) is an N-glycosylated plasma protein that plays an important role in indicating different stages of type 1 diabetes .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-10555

AMG-221	11β-HSD	Metabolic Disease
AMG-221 is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) with a K_i of 12.8 nM in vitro biochemical scintillation proximity assay (SPA) and an IC₅₀ of 10.1 nM in cell-based assays . AMG-221 can be used for the research of type 2 diabetes .

HY-138688

Cinnamyl-3,4-dihydroxy-α-cyanocinnamate CDC	Lipoxygenase	Metabolic Disease Cancer
Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus .

HY-164595

IHMT-MST1-39	Hippo (MST) Apoptosis AMPK	Metabolic Disease
IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC₅₀ of 42, 109, 286, 159 nM for MST1, MST2, MST3, MST4. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 can be used for the studies of type 1 diabetes (T1D) and type 2 diabetes (T2D) .

HY-126042

(±)-Lisofylline (±)-Lisophylline	Interleukin Related	Metabolic Disease Inflammation/Immunology
(±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research .

HY-177284

Steroid sulfatase-IN-10	Steroid Sulfatase	Inflammation/Immunology
Steroid sulfatase-IN-10 (Example 216) is a Steroid sulfatase inhibitor with an IC₅₀ of 0.03-0.27 µM . Steroid sulfatase-IN-10 can be used for inflammatory diseases such as rheumatoid arthritis, type 1 and 2 diabetes and systemic lupus erythematosus research .

HY-P1745

InsB (9-23) Insulin B chain (9-23)	MHC	Inflammation/Immunology
InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. InsB (9-23) can be used to treat a number of autoimmune related diseases like Type 1 diabetes .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-122028

HSD-016	11β-HSD	Metabolic Disease
HSD-016 is a potent, selective and orally active *11β-hydroxysteroid dehydrogenase type 1* (11β-HSD1) inhibitor with IC₅₀** values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes research .

HY-W142432

Perfluoroundecanoic acid	Biochemical Assay Reagents β-catenin Wnt Arginase TGF-beta/Smad mTOR Akt ERK Atg8/LC3 p62 Autophagy	Metabolic Disease Inflammation/Immunology Cancer
Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation .

HY-151257

IHMT-MST1-58	Hippo (MST)	Metabolic Disease
IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC₅₀ value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-109854A

(R)-Lisofylline (R)-Lisophylline	STAT	Metabolic Disease Inflammation/Immunology
(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC₅₀ of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research .

HY-126042R

(±)-Lisofylline (Standard) (±)-Lisophylline (Standard)	Interleukin Related Reference Standards	Metabolic Disease Inflammation/Immunology
(±)-Lisofylline (Standard) is the analytical standard of (±)-Lisofylline. This product is intended for research and analytical applications. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research .

HY-128574

D927 DS11252927	GLUT PI3K Akt	Metabolic Disease
D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC₅₀ of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes .

HY-N11723

Catenarin Katenarin	CCR CXCR p38 MAPK JNK Calcium Channel	Infection Metabolic Disease Inflammation/Immunology
Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice ^[1][2].

HY-126042S4

(±)-Lisofylline-d4 (±)-Lisophylline-d₄	Isotope-Labeled Compounds Interleukin Related	Metabolic Disease Inflammation/Immunology
(±)-Lisofylline-d₄ ((±)-Lisophylline-d₄) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research .

HY-176865

Anti-inflammatory agent 106	Drug Derivative	Inflammation/Immunology
Anti-inflammatory agent 106 (Example 2) is a derivative of Paeonol (HY-N0159). Anti-inflammatory agent 106 has potent anti-inflammatory activity. Anti-inflammatory agent 106 effectively inhibits xylene-induced ear swelling in mouse models. Anti-inflammatory agent 106 can be used for inflammatory diseases like rheumatoid arthritis, psoriasis and type 1 diabetes research .

HY-125316

AMG-151 ARRY-403	Endogenous Metabolite	Metabolic Disease
AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .

HY-138990

GK563	Phospholipase Apoptosis	Inflammation/Immunology
GK563 is a selective Ca ²⁺-independent phospholipase A₂ (GVIA iPLA₂) inhibitor with an IC₅₀ value of 1 nM. GK563 is 22000 times more active against GVIA iPLA₂ than GIVA cPLA₂. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes .

HY-142295

GNF2133 1 Publications Verification	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .

HY-142295A

GNF2133 hydrochloride	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .

HY-W008947

SEW2871 Maximum Cited Publications 7 Publications Verification	LPL Receptor ERK Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC₅₀ of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .

HY-W008947R

SEW2871 (Standard)	LPL Receptor ERK Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
SEW2871 is an orally active, potent, highly selective S1P1 (sphingosine-1-phosphate type 1 receptor) agonist, with an EC50 of 13.8 nM. SEW2871 activates ERK, Akt, and Rac signaling pathways and induces S1P1 internalization and recycling. SEW2871 reduces lymphocyte numbers in blood. SEW2871 can be used for the research of diabetes, Alzheimer’s disease, liver fibrosis, and inflammatory responses .

HY-P5396A

GAD65 (524-543) acetate	Amino Acid Decarboxylase	Others
GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .

HY-P5396

GAD65 (524-543)	Amino Acid Decarboxylase	Others
GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .

HY-145492

Δ7(Z)-C14-HSL N-(3-Oxo-7Z-tetradecenoyl)-L-homoserine lactone	Others	Inflammation/Immunology
Δ7(Z)-C14-HSL (Compound 12) is an immunosuppressive agent that can inhibit the proliferation of mouse splenic cells with an IC₅₀ of 17 μM. Δ7(Z)-C14-HSL can be used for further studying its potential as a molecular mechanism in TNF-R-driven immune diseases, especially autoimmune diseases such as psoriasis, rheumatoid arthritis, and type 1 diabetes .

HY-P99959

Unasnemab MT-3921; rH116A3	TGF-β Receptor	Neurological Disease
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .

HY-124665

LMP-420	TNF Receptor Interleukin Related	Infection Metabolic Disease Inflammation/Immunology
LMP-420 is a selective tumor necrosis factor-α (TNF-α) inhibitor. LMP-420 reduces the release of pro-inflammatory cytokines (e.g., IL-1β, IL-2), inducing the expression of anti-inflammatory cytokine IL-10 and anti-apoptotic molecules SOCS-1 and Mn-SOD. LMP-420 also downregulates chemokines (e.g., IP-10, MCP-1) to reduce immune cell infiltration. LMP-420 is promising for research of type 1 diabetes mellitus, inflammatory diseases (e.g., colitis), and HIV-Mycobacterium tuberculosis coinfection .

HY-161449

JTT-654	11β-HSD	Metabolic Disease
JTT-654 is an orally active, potent and selective11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. The IC₅₀ of JTT-654 for 11β-HSD1 is 4.65, 0.97, and 0.74 nM in human, rat, and mouse recombinant enzymes, respectively. JTT-654 showed competitive inhibition against human recombinant enzyme. The IC₅₀ value for human 11β-HSD2 is > 30 μM (human 11β-HSD2 is responsible for the reverse reaction against human 11β-HSD1). JTT-654 ameliorates insulin resistance and non-obese type 2 diabetes by inhibiting adipose tissue and liver 11β-HSD1 .

HY-P990001

Anti-Mouse IL-10 Antibody (JES5-2A5)	Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .

Cat. No.	Product Name	Type

HY-158525

A3G3S3 glycan A3G3S3 N-linked oligosaccharide	Carbohydrates
A3G3S3 glycan (A3G3S3 N-linked oligosaccharide) is an N-glycosylated plasma protein that plays an important role in indicating different stages of type 1 diabetes .

Cat. No.	Product Name	Target	Research Area

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P10512

BDC2.5 mimotope	Peptides	Others
BDC2.5 mimotope is a potent antigen-mimicking peptide that can activate CD4+ T cell populations that have the same antigen recognition properties as BDC2.5 cells. BDC2.5 mimotope can be used to study the prevention or treatment of type 1 diabetes by targeting specific T cell populations .

HY-P5396A

GAD65 (524-543) acetate	Amino Acid Decarboxylase	Others
GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .

HY-109552

Pramlintide acetate hydrate	Peptides	Metabolic Disease
Pramlintide acetate hydrate is the acetate hydrate of Pramlintide (HY-P0058). Pramlintide acetate hydrate can be used for the stufy of type 1 and type 2 diabetes .

HY-P10612

Tetanus toxin peptide	Bacterial	Metabolic Disease
Tetanus toxin peptide is a specific peptide isolated from the toxin produced by Clostridium tetani. Tetanus toxin peptide can be used as an immunogen to induce diabetes in mice. Tetanus toxin peptide can be used in the study of type 1 diabetes .

HY-P1745

InsB (9-23) Insulin B chain (9-23)	MHC	Inflammation/Immunology
InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. InsB (9-23) can be used to treat a number of autoimmune related diseases like Type 1 diabetes .

HY-P10492

Tregitope 289	Peptides	Others Metabolic Disease
Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved T cell epitope that stimulates the expansion of natural regulatory T cells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .

HY-P5396

GAD65 (524-543)	Amino Acid Decarboxylase	Others
GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .

HY-P5488

BDC2.5 Mimotope 1040-63	Peptides	Others
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)

Cat. No.	Product Name	Target	Research Area

HY-P99211

Otelixizumab ChAglyCD3; TRX 4	CD3	Metabolic Disease
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .

HY-P99383

Volagidemab REMD-477; AMG-477	GCGR	Metabolic Disease
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99959

Unasnemab MT-3921; rH116A3	TGF-β Receptor	Neurological Disease
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .

HY-P990001

Anti-Mouse IL-10 Antibody (JES5-2A5)	Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) .

HY-P991326

BL-9020 EDP-10; JHL-1311	Interleukin Related	Endocrinology
BL-9020 is a human monoclonal antibody (mAb) targeting NKp46/NCR1. BL-9020 can be used in type 1 diabetes mellitus research.

HY-P991552

AFM15	CD3	Metabolic Disease Inflammation/Immunology
AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11723

Catenarin Katenarin	Quinones Microorganisms Anthraquinones Source classification	CCR CXCR p38 MAPK JNK Calcium Channel
Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice ^[1][2].

Cat. No.	Product Name	Chemical Structure

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-126042S4

(±)-Lisofylline-d4

(±)-Lisofylline-d₄ ((±)-Lisophylline-d₄) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

type 1 diabetes

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products